Evidence map›Paper›PMID 42219154›Full record

Trial reportBritish journal of clinical pharmacology2026

Evaluation of a pantoprazole and 4-desmethylpantoprazole-sulfate metabolic ratio as a novel CYP2C19 phenotyping method.

Julian Peter Müller, Vladimir N Belov, Sabrina Yamoune, Bob Miller, Mohammed Hasoumi, Jolanta Tupiec, Thea Laurentius, L Cornelius Bollheimer, Julia C Stingl, Katja S Just

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Julian Peter MüllerInstitute of Clinical Pharmacology, University Hospital RWTH Aachen, Aachen, North Rhine-Westphalia, Germany.ORCID https://orcid.org/0009-0002-1505-5664
Vladimir N BelovDepartment of NanoBiophotonics, Max Planck Institute for Multidisciplinary Sciences (MPI-NAT), Göttingen, Lower Saxony, Germany.
Sabrina YamouneInstitute of Clinical Pharmacology, University Hospital RWTH Aachen, Aachen, North Rhine-Westphalia, Germany.
Bob MillerInstitute of Clinical Pharmacology, University Hospital RWTH Aachen, Aachen, North Rhine-Westphalia, Germany.
Mohammed HasoumiInstitute of Clinical Pharmacology, University Hospital RWTH Aachen, Aachen, North Rhine-Westphalia, Germany.
Jolanta TupiecInstitute of Clinical Pharmacology, University Hospital RWTH Aachen, Aachen, North Rhine-Westphalia, Germany.
Thea LaurentiusDepartment of Geriatric Medicine, University Hospital RWTH Aachen, Aachen, North Rhine-Westphalia, Germany.
L Cornelius BollheimerDepartment of Geriatric Medicine, University Hospital RWTH Aachen, Aachen, North Rhine-Westphalia, Germany.
Julia C StinglInstitute of Clinical Pharmacology, University Hospital RWTH Aachen, Aachen, North Rhine-Westphalia, Germany.
Katja S JustInstitute of Clinical Pharmacology, University Hospital RWTH Aachen, Aachen, North Rhine-Westphalia, Germany.ORCID https://orcid.org/0000-0002-6782-8078

Funding

B. Braun-Stiftung BBST-D-21-00027Deutsche Forschungsgemeinschaft 455749974Interdisziplinäres Zentrum für Klinische Forschung (IZKF) Aachen PTD 1-9
6 · The paper itself

Abstract

aimsCYP2C19 is one of the most important pharmacogenes, and its activity is highly variable due to factors such as genetics or drug-drug interactions. Due to the lack of an appropriate endogenous CYP2C19 biomarker, surrogate methods to assess its activity are warranted. The aim of this work was to validate pantoprazole as a CYP2C19 phenotyping drug.

methodsWe performed a single-dose pharmacokinetic study with 20 healthy participants in a randomized cross-over design. Participants received 10 mg omeprazole and 20 mg pantoprazole on two different study days with a washout phase of one week. Blood sampling was performed at 14 time points spanning 8 h after drug administration. Drug and metabolite plasma concentrations were assessed by LC-MS/MS. Metabolic ratios (MR) of metabolite/substrate were formed using the area under the curve from 0 to 8 h (AUC

resultsWe demonstrate very strong correlations (Spearman ρ = 0.84) of AUC

conclusionsIn contrast to omeprazole, pharmacokinetics of pantoprazole are described to be stable during repeated dosing, which may allow phenotyping of CYP2C19 with patients using pantoprazole MRs in situations where pantoprazole is part of the prescribed medication.

Indexed as

Cytochrome P-450 CYP2C19Cytochrome P-450 CYP2C19 InhibitorsPantoprazoleProton Pump InhibitorsAdultArea Under CurveCross-Over StudiesFemaleHumansMaleOmeprazolePhenotypeTandem Mass SpectrometryYoung AdultCYP2C19 protein, humanCytochrome P-450 CYP2C19Cytochrome P-450 CYP2C19 InhibitorsOmeprazolePantoprazoleProton Pump InhibitorsCYP2C19cytochrome P450drug–drug interactionspersonalized medicinepharmacogeneticspharmacokinetics

Identifiers

PMID42219154
PMCPMC13619035

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.